Back to search
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which EGFR Mutation Positive Advanced Non Small Cell Lung Cancer trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which EGFR Mutation Positive Advanced Non Small Cell Lung Cancer trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participa…
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center. T…
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell…
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerabili…
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in…
EGFR-mutated advanced NSCLC patients without ctDNA clearance after lead-in osimertinib monotherapy have inferior PFS compared with those with ctDNA clearance. C…
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Recepto…
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage…